Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review

Flora Shan1, Sonya MacVicar2, Karel Allegaert3,4

  • 1Department of Pediatric and Child Health, University of Manitoba, 405 Chown, 753 McDermot Ave., Winnipeg, MB, R3E0T6, Canada.

Trials
|March 14, 2020
PubMed

Insights

Neonatal opioid withdrawal lacks standardized outcome reporting, hindering effective treatment guidelines. Developing a core outcome set is crucial for consistent research and improved care for affected families.

Area of Science:

  • Neonatal Abstinence Syndrome (NAS) research
  • Evidence-based medicine
  • Clinical trial methodology

Background:

  • Neonatal withdrawal from in utero opioid exposure is a significant global health issue.
  • Existing research lacks standardized outcome measurement, impeding evidence synthesis.
  • Randomized controlled trials are vital for identifying effective treatments.

Purpose of the Study:

  • To identify and categorize outcomes reported in the literature for neonatal opioid withdrawal.
  • To assess the consistency in outcome selection, definition, and reporting.
  • To highlight the need for a standardized core outcome set.

Main Methods:

  • Comprehensive literature search of major databases (MEDLINE, EMBASE, Cochrane Central) from July 2007 to July 2017.
  • Inclusion of various study designs, including RCTs, observational studies, and guidelines.
  • Extraction and categorization of primary and secondary neonatal outcomes using OMERACT core areas.

Main Results:

  • 107 primary and 127 secondary outcomes were identified across 47 articles.
  • Most frequent outcomes: duration of pharmacotherapy, hospital stay, and withdrawal symptoms.
  • Significant heterogeneity in outcome definitions and measurement, with no parent involvement.

Conclusions:

  • Inconsistent outcome reporting in neonatal opioid withdrawal literature is a major limitation.
  • Lack of standardized definitions and parent involvement hinders evidence synthesis.
  • Development of a core outcome set is imperative for advancing clinical practice and guidelines.
Abstract

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
824
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.4K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
760
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.7K